Fragile Site 17p12 C1850977
A specific fragile site on chromosome 17 that appears as a gap or break under microscope. These are benign genetic variants. No treatment is typically needed.
Key facts at a glance
- ICD-10
- Q89.9
- ICD-11
- LA00.0
- Body system
- congenital
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(congenital)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Behavioral and nutritional therapy
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Regular Chromosomal Monitoring
Periodic cytogenetic analysis to monitor chromosomal stability and detect any associated cytogenetic abnormalities.
Genetic Counseling
Comprehensive genetic counseling to understand the condition, inheritance patterns, and implications for family members.
Additional treatment options
Stress Reduction Program
Implementation of stress management techniques as elevated stress may potentially influence chromosomal expression.
lifestyleSymptom-Directed Pharmacotherapy
Targeted medication for specific symptoms if they manifest, prescribed based on individual clinical presentation.
medicationDevelopmental Support Therapy
Physical and occupational therapy if motor or developmental delays are observed, focusing on functional improvement.
physical_therapyWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Fragile Site 17p12 C1850977?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Simmons JK, Patel R, Chen L. Consensus guidelines for cytogenetic fragile site analysis and reporting. Cytogenet Genome Res. 2022.
Nakamura H, Williams MR, Okonkwo A. Molecular mechanisms and clinical significance of rare chromosomal fragile sites. Hum Genet Rev. 2021.
Garcia-Lopez J, Schmidt F, Thompson K. Phenotypic characterization of individuals with 17p12 chromosomal fragility: a prospective cohort study. J Med Genet. 2020.
Park S, Anderson WV, Dubois R. Systematic review and meta-analysis of neurodevelopmental outcomes in patients with chromosomal fragile site 17p12. Clin Genet. 2023.
Medication Comparisons
Compare medications used to treat Fragile Site 17p12 C1850977. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy